Clinical review report: Siponimod (Mayzent) (Novartis Pharmaceuticals Canada Inc.) indication : secondary-progressive multiple sclerosis
The objective of this report is to perform a systematic review of the beneficial and harmful effects of siponimod for the treatment of adult patients with secondary-progressive multiple sclerosis with active disease, as per the Health Canada indication
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, September 2020
|
| Edition: | Version: Final (with redactions) |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this report is to perform a systematic review of the beneficial and harmful effects of siponimod for the treatment of adult patients with secondary-progressive multiple sclerosis with active disease, as per the Health Canada indication |
|---|---|
| Physical Description: | 1 PDF file (122 pages) illustrations |